Pfizer
- Thomas A Wynn
Thomas Wynn currently serves as Vice President of Discovery for Inflammation and Immunology at Pfizer, a position held since July 2017, focusing on areas such as gastroenterology, dermatology, rheumatology, neuroinflammation, immuno-oncology, and metabolic disease, with expertise in the immunology of infectious diseases and respiratory disorders. Prior to Pfizer, Thomas Wynn worked at the National Institute of Allergy and Infectious Diseases from 2002 to July 2017, where responsibilities included serving as Senior Investigator and Chief of the Immunopathogenesis Section, concentrating on chronic inflammation, tissue repair, and fibrosis. Additionally, Thomas Wynn contributed to the NIH-Oxford-Cambridge Scholars Program as Scientific Director from July 2011 to June 2017 and held roles including Deputy Director and Investigator at the National Institutes of Health. A PhD in Microbiology and Immunology was obtained from the University of Wisconsin-Madison between 1986 and 1991.
Org chart
Upgrade to view 0 reports
Teams
This person is not in any teams
Offices
This person is not in any offices
Pfizer
532 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.
